Evidence map›Paper›PMID 29581593›Full record

ArticleNature cell biology2018

L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage.

Somaira Nowsheen, Khaled Aziz, Asef Aziz, Min Deng, Bo Qin, Kuntian Luo, Karthik B Jeganathan, Henan Zhang, Tongzheng Liu, Jia Yu and 5 more

Abstract read
In one paragraph

Article in Nature cell biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Epigenetic silencingCancer biology & therapy · 2026
    Article
  3. ADSCs-Exo ameliorates UVB-induced skin DNA damage via p62-RNF168-dependent histone ubiquitination.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Article
  4. Article
  5. Article
  6. Exploration of targeted anti-tumor therapy · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Somaira NowsheenMayo Medical Scientist Training Program, Mayo Clinic School of Medicine and Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-7174-5366
Khaled AzizMayo Medical Scientist Training Program, Mayo Clinic School of Medicine and Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA.
Asef AzizDepartment of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
Min DengDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Bo QinDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Kuntian LuoDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Karthik B JeganathanDepartment of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
Henan ZhangDepartment of Hematology, Mayo Clinic, Rochester, MN, USA.
Tongzheng LiuDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Jia YuDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Yibin DengLaboratory of Cancer Genetics, The University of Minnesota Hormel Institute, Austin, MN, USA.
Jian YuanDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Wei DingDepartment of Hematology, Mayo Clinic, Rochester, MN, USA.
Jan M van DeursenDepartment of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
Zhenkun LouDepartment of Oncology, Mayo Clinic, Rochester, MN, USA. lou.zhenkun@mayo.edu.ORCID 0000-0003-1938-3091
Mayo Clinic · USMayo Clinic in Arizona · USMayo Clinic in Florida · USJinan University · CNUniversity of Minnesota · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Targeted MV-CEA as a Potent Antitumor Agent against GBMP50CA108961 · NCI · MAYO CLINIC ROCHESTER · PI O'NEILL, BRIAN PATRICK · 2004 to 2015
$22.5M
Ubiquitination and the DNA Damage Response PathwayR01CA130996 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2008 to 2018
$3.3M
Regulation of homologous recombination and cancer cell response to chemoradiotherapyR01CA203561 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2016 to 2020
$1.8M
Deubiquitinases in regulation of BRCA1 pathwayR01CA203971 · NCI · MAYO CLINIC ROCHESTER · PI KAUFMANN, SCOTT H, LOU, ZHENKUN · 2016 to 2020
$1.8M
Regultion of p53 DeubiquitinationR01CA148940 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2011 to 2015
$1.6M
Gain of function mutant p53 in telomere uncapping-driven breast tumorigenesisR01CA160333 · NCI · UNIVERSITY OF MINNESOTA · PI DENG, YIBIN · 2011 to 2015
$1.2M
NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA108961NCI NIH HHS R01 CA130996NCI NIH HHS R01 CA148940NCI NIH HHS R01 CA160333NCI NIH HHS R01 CA203561NCI NIH HHS R01 CA203971
6 · The paper itself

Abstract

Cells respond to cytotoxic DNA double-strand breaks (DSBs) by recruiting DNA repair proteins to the damaged site. This recruitment is dependent on ubiquitylation of adjacent chromatin areas by E3 ubiquitin ligases such as RNF8 and RNF168, which are recruited sequentially to the DSBs. However, it is unclear what dictates the sequential order and recruits RNF168 to the DNA lesion. Here, we reveal that L3MBTL2 (lethal(3)malignant brain tumour-like protein 2) is the missing link between RNF8 and RNF168. We found that L3MBTL2 is recruited by MDC1 and subsequently ubiquitylated by RNF8. Ubiquitylated L3MBTL2, in turn, facilitates recruitment of RNF168 to the DNA lesion and promotes DNA DSB repair. These results identify L3MBTL2 as a key target of RNF8 following DNA damage and demonstrates how the DNA damage response pathway is orchestrated by ubiquitin signalling.

Indexed as

DNA Breaks, Double-StrandedDNA RepairSignal TransductionAdaptor Proteins, Signal TransducingAtaxia Telangiectasia Mutated ProteinsCell Cycle ProteinsDNA-Binding ProteinsHEK293 CellsHumansNuclear ProteinsOsteosarcomaPhosphorylationProtein TransportTrans-ActivatorsTranscription FactorsUbiquitinationAdaptor Proteins, Signal TransducingAtaxia Telangiectasia Mutated ProteinsATM protein, humanCell Cycle ProteinsDNA-Binding ProteinsL3MBTL2 protein, humanMDC1 protein, humanNuclear ProteinsRNF168 protein, humanRNF8 protein, humanTrans-ActivatorsTranscription FactorsUbiquitin-Protein Ligases

Identifiers

PMID29581593
PMCPMC6083879
OpenAlexW2794949782

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.